Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Transcept Pharmaceuticals Announces Expected FDA Extension Of Regulatory Review Period For Intermezzo(R)
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced that the U.S. Food and Drug Administration (FDA) has informed the company that it should expect to receive formal notice of a three month extension of the review period for the new drug application (NDA) for Intermezzo(R) (zolpidem tartrate sublingual tablet). The Intermezzo(R) NDA had been assigned a Prescription Drug User Fee Act (PDUFA) date of July 30, 2009. Under this revised timeline, Transcept now anticipates action from the FDA on the NDA on or before October 31, 2009.
pharmacy online
Body Chemistry May Identify Type 2 Risk, UK
Body chemistry changes that lead to Type 2 diabetes begin several years before symptoms become apparent, according to new research.
News of the day
CellScope Project To Bring Low-Cost Lab Tools To The Field
Researchers at the University of California, Berkeley, are proving that a camera phone can capture far more than photos of people or pets at play. They have now developed a cell phone microscope, or CellScope, that not only takes color images of malaria parasites, but of tuberculosis bacteria labeled with fluorescent markers.
Diagnostics

Follow-Up Study Further Reinforces The Long-Term Benefits Of Tight Glucose Control In Early Treatment Of Diabetes

A study published in today"s issue of the Archives of Internal Medicine provides further reinforcement that tight control of blood glucose as soon as possible after a diagnosis of type 1 diabetes yields long-term benefits with regard to lowering the rates of eye, kidney and heart complications associated with diabetes. These findings stem from the landmark Diabetes Control and Complications Trial (DCCT) and its follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC), both funded by the National Institutes of Health. The results of this study indicate that after 30 years of diabetes, the incidence of eye damage was cut by more than half; kidney disease was reduced by almost two-thirds; and heart disease by almost one-half in those individuals who achieved tight glucose control for over 6 years early in the course of their diabetes. The importance of glucose control in diabetes has been firmly established, but this follow-up data provides even more reinforcement to clinicians -- and their patients -- about the long-term benefits of early glucose control. Evidence from the DCCT-EDIC, as well as the U.K. Prospective Diabetes Study (UKPDS) and its follow-up study in type 2 diabetes show that improved glucose control to a level of approximately 7 percent reduces the complications of diabetes dramatically. The study also acknowledges that treatment innovations over the past 20 years, such as insulin pumps and analogues, along with the improved treatment of co-occurring illnesses such as high blood pressure and cholesterol have contributed to improvements in the management of diabetes. When it comes to diabetes, it is important for health care providers and their patients to remember the ABCs of diabetes: - A is for A1C (a measure of average glucose). Most people with diabetes should get an A1C test at least twice a year, which measures how well blood glucose has been controlled over the past 2-3 months. The goal for most people with diabetes is an A1C of less than 7%, which is an estimated average glucose of less than 154 mg/dl. - B is for blood pressure. People with diabetes should have a target blood pressure of less than 130/80 mmHg. - C is for cholesterol. LDL (bad) cholesterol should be below 100 mg/dl. American Diabetes Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009